HRP2

HRP2. Histidine-rich protein 2 is a crucial antigen produced exclusively by the malaria parasite Plasmodium falciparum. It is released into the bloodstream of infected individuals and serves as the primary target for many rapid diagnostic tests used globally. The protein's unique structure and genetic characteristics have significant implications for malaria control and elimination efforts, particularly in regions where diagnostic failures due to genetic mutations are emerging.

Overview

HRP2 was first identified as a major metabolic product of the blood-stage parasite and has since become a cornerstone of malaria diagnostics. Its discovery was pivotal for the development of immunochromatographic rapid diagnostic tests, which revolutionized case management by enabling quick, microscopy-free confirmation of infection. The World Health Organization recommends these tests for guiding treatment in endemic areas, making HRP2 a critical tool in the global fight against malaria. The widespread adoption of these diagnostics has been supported by organizations like the President's Malaria Initiative and the Global Fund to Fight AIDS, Tuberculosis and Malaria.

Structure and function

The protein is characterized by extensive repeats of amino acid sequences rich in histidine and alanine, which are encoded by the pfhrp2 gene located on chromosome 8 of the Plasmodium falciparum genome. These repetitive motifs are highly immunogenic, allowing for sensitive detection by monoclonal antibodies in diagnostic assays. While its precise biological function within the parasite is not fully understood, HRP2 is implicated in the detoxification of heme during hemoglobin digestion in the parasite's food vacuole. Research from institutions like the National Institutes of Health and Wellcome Trust continues to investigate its role in parasite biology and host-pathogen interactions.

Role in malaria diagnosis

HRP2-based rapid tests work by capturing the antigen on a nitrocellulose strip using specific antibodies, producing a visible line to indicate infection. These tests are extensively used across Sub-Saharan Africa, Southeast Asia, and the Amazon Basin due to their ease of use and high sensitivity for detecting Plasmodium falciparum. They have been instrumental in implementing the WHO's "test-and-treat" policy, reducing the indiscriminate use of artemisinin-based combination therapies. Major manufacturers, including Abbott Laboratories and SD Biosensor, produce these tests, which are procured by entities like UNICEF for national control programs.

Genetic diversity and deletions

Natural variation in the pfhrp2 gene sequence across different parasite strains can affect the binding efficiency of diagnostic antibodies, potentially leading to false-negative results. More critically, complete deletions of the pfhrp2 gene, and often the homologous pfhrp3 gene, have been documented in parasites from the Peruvian Amazon, Eritrea, and parts of India. These deletions result in parasites that are invisible to HRP2-based tests, posing a severe challenge for diagnosis. Surveillance studies led by the Centers for Disease Control and Prevention and the WorldWide Antimalarial Resistance Network monitor the prevalence and spread of these deletion mutants.

Implications for public health

The emergence and spread of pfhrp2/3-deleted parasites threaten to undermine malaria control programs reliant on HRP2-based diagnostics. This can lead to missed cases, continued transmission, and inappropriate treatment, potentially exacerbating morbidity and mortality. In response, the World Health Organization has issued guidelines for surveillance and transition to alternative diagnostic methods, such as tests targeting parasite lactate dehydrogenase or microscopy, in affected regions. Ongoing research and development efforts, supported by agencies like the Bill & Melinda Gates Foundation, focus on creating next-generation diagnostics to ensure resilient malaria case management worldwide. Category:Malaria Category:Proteins Category:Medical diagnostics